David Ivars
University of Valencia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David Ivars.
Leukemia Research | 2013
Vera Adema; Jesús Hernández; María Abáigar; Eva Lumbreras; Esperanza Such; Anna Calull; Esther Dominguez; Leonor Arenillas; Mar Mallo; José Cervera; Isabel Marugán; Mar Tormo; F. García; Teresa González; Elisa Luño; Carmen Sanzo; María Luisa Martín; Manuela Fernández; Dolors Costa; Beatriz Segovia Blázquez; Beatriz Barreña; Fernando Marco; Ana Batlle; Ismael Buño; Carolina Martínez-Laperche; Victor Noriega; Rosa Collado; David Ivars; Felix Carbonell; Isabel Vallcorba
Chromosomal abnormalities are detected in 40-60% of patients with de novo myelodysplastic syndromes (MDS). This study used the FISH technique in 773 patients with de novo MDS without evidence of monosomy 7 (-7) or 7q deletion (7q-) by conventional G-banding cytogenetics (CC) to analyze their prognostic impact by FISH alone. FISH detected -7/7q- in 5.2% of patients. Presence of -7/7q- was associated with shorter overall survival than absence of such aberrations. Our results suggest that FISH 7q could be beneficial in patients with intermediate WHO morphologic risk stratification and no evidence of -7/7q- by CC.
Oncotarget | 2016
Gonzalo Blanco; Anna Puiggros; Panagiotis Baliakas; Anastasia Athanasiadou; MªDolores García-Malo; Rosa Collado; Aliki Xochelli; María Rodríguez-Rivera; Margarita Ortega; Mª José Calasanz; Elisa Luño; MªTeresa Vargas; Javier Grau; Carolina Martínez-Laperche; Alberto Valiente; José Cervera; Achilles Anagnostopoulos; Eva Gimeno; Eugenia Abella; Evangelia Stalika; Jesús Mª Hernández-Rivas; Francisco José Ortuño; Diego Robles; Ana Ferrer; David Ivars; Marcos González; Francesc Bosch; Pau Abrisqueta; Kostas Stamatopoulos; Blanca Espinet
Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p−) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p− and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P < 0.05) higher incidence of a complex karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10-year overall survival (OS), 8p− (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup.
BioMed Research International | 2014
Rosa Collado; David Ivars; Isabel Oliver; Carmen Tormos; Mercedes Egea; Amparo Miguel; Guillermo T. Sáez; Felix Carbonell
Oxidative stress contributes to genomic instability in chronic lymphocytic leukemia (CLL), but its relationship with the acquisition of specific chromosomal abnormalities is unknown. We recruited 55 untreated CLL patients and assessed 8-oxo-2′-deoxyguanosine (8-oxo-dG), glutathione, and malondialdehyde (MDA) levels, and we compared them among the cytogenetic subgroups established using fluorescence in situ hybridization (FISH). Significant increases in 8-oxo-dG and/or MDA were observed in patients with unfavorable cytogenetic aberrations (17p and 11q deletions) compared to the 13q deletion group. TP53 deletion patients exhibited a diminished DNA repair efficiency. Finally, cases with normal FISH also showed enhanced 8-oxo-dG, which could result in adverse outcomes.
Leukemia Research | 2017
Kamila Janusz; Mónica del Rey; María Abáigar; Rosa Collado; David Ivars; María Hernández-Sánchez; Alberto Valiente; Cristina Robledo; Rocío Benito; María Díez-Campelo; Fernando Ramos; Alexander Kohlmann; Consuelo del Cañizo; Jesús María Hernández-Rivas
Our study aimed to analyze the presence of mutations in SF3B1 and other spliceosome-related genes in myelodysplastic syndromes with ringed sideroblasts (MDS-RS) by combining conventional Sanger and next-generation sequencing (NGS) methods, and to determine the feasibility of this approach in a clinical setting. 122 bone marrow samples from MDS-RS patients were studied. Initially, exons 14 and 15 of the SF3B1 gene were analyzed by Sanger sequencing. Secondly, they were studied by NGS covering besides SF3B1, SRSF2, U2AF1 and ZRSR2 genes. An 86% of all patients showed mutations in the SF3B1 gene. Six of them, which were not identifiable by conventional sequencing in the first diagnostic step, were revealed by NGS. In addition, 19.5% of cases showed mutations in other splicing genes: SRSF2, U2AF1, and ZRSR2. Furthermore, 8.7% of patients had two mutations in SF3B1, SF3B1 and SRSF2, and SF3B1 and U2AF1, while 5.7% showed no mutations in the four spliceosome-related genes analyzed. The combined use of conventional Sanger and NGS allows the identification of mutations in spliceosome-related genes in almost all MDS patients with RS. This two-step approach is affordable and could be useful as a complementary technique in cases with an unclear diagnosis.
Leukemia & Lymphoma | 2015
Sílvia Saumell; Lourdes Florensa; María Rodríguez-Rivera; Carme Pedro; Jesús María Hernández-Rivas; Eva Lumbreras; María Abáigar; Rosa Collado; David Ivars; Felix Carbonell; Isabel Marugán; Mar Tormo; Mercedes Botia; María Ángeles Piñan; Idoia Ancín; Teresa González; Nicolás Díaz Varela; Javier Grau; Isabel Granada; Neus Ruiz; Maria Luisa Martin; Manuela Fernández-Guijarro; José-Joaquín Duarte; María José Calasanz; María José Larrayoz; Francesc Solé
S í lvia Saumell 1,2,3 , Lourdes Florensa 1,2 , Mar í a Rodr í guez-Rivera 1,2 , Carme Pedro 1,2 , Jes ú s Mar í a Hern á ndez-Rivas 4 , Eva Lumbreras 4 , Mar í a Ab á igar 4 , Rosa Collado 5 , David Ivars 5 , F é lix Carbonell 5 , Isabel Marug á n 6 , Mar Tormo 6 , Mercedes Botia 6 , Mar í a Á ngeles Pi ñ an 7 , Idoia Anc í n 7 , Teresa Gonz á lez 8 , Nicol á s D í az Varela 8 , Javier Grau 9 , Isabel Granada 9 , Neus Ruiz 9 , Mar í a Luisa Mart í n 10 , Manuela Fern á ndez-Guijarro 10 , Jos é -Joaqu í n Duarte 11 , Mar í a Jos é Calasanz 12 , Mar í a Jos é Larrayoz 12 & Francesc Sol é 13
Cancer Letters | 2012
Rosa Collado; Isabel Oliver; Carmen Tormos; Mercedes Egea; Amparo Miguel; Concha Cerdá; David Ivars; Silvia Borrego; Félix Carbonell; Guillermo T. Sáez
Clinical Biochemistry | 2017
David Ivars; Maria Teresa Orero; Karla Javier; Laura Díaz-Vico; José Luis García-Giménez; Salvador Mena; Carmen Tormos; Mercedes Egea; Pérez Pl; Beatriz Arrizabalaga; María Ángeles Ruiz; Nuria Yagüe; Mar Tormo; Reyes Sancho-Tello; Angela Gomes; Carmen Alguero; José-Enrique O'Connor; Guillermo T. Sáez; Félix Carbonell; Rosa Collado
Cancer Letters | 2017
Rosa Collado; Anna Puiggros; José Antonio López-Guerrero; Mª José Calasanz; Mª José Larráyoz; David Ivars; Zaida García-Casado; Eugenia Abella; Ma Teresa Orero; Elisabet Talavera; Ana Oliveira; Jesús Mª Hernández-Rivas; María Hernández-Sánchez; Elisa Luño; Alberto Valiente; Javier Grau; Inmaculada Portal; Santiago Gardella; Anna Camino Salgado; Ma Teresa Giménez; Mª Teresa Ardanaz; Andrea Campeny; José Julio Hernández; Sara Alvarez; Blanca Espinet; Felix Carbonell
Haematologica | 2016
Gonzalo Blanco; Anna Puiggros; Panagiotis Baliakas; Anastasia Athanasiadou; MªDolores García-Malo; Rosa Collado; Aliki Xochelli; María Rodríguez-Rivera; Margarita Ortega; Mª José Calasanz; Elisa Luño; María Teresa Vargas; Javier Grau; Carolina Martínez-Laperche; Alberto Valiente; G. Papaioannou; José Cervera; Achilles Anagnostopoulos; M. A. Pinan; Evangelia Stalika; Jesús Mª Hernández-Rivas; A. Batlle; Marta Salido; Francisco José Ortuño; Carme Melero; D. Robles; Ana Ferrer; David Ivars; Alicia Rodríguez; Marcos González
Leukemia Research | 2015
M. Del Rey; Kamila Janusz; María Abáigar; Rosa Collado; David Ivars; Alberto Valiente; M. Hernández; M. Diez-Campelo; Fernando Ramos; J. Sánchez-Real; C. del Cañizo; Jesús-María Hernández-Rivas